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Abstract
Lymphopenia is associated with an increased mortality in several medical conditions. Its prognostic impact in
myelodysplastic syndromes (MDS) is less well studied. Hence, we analyzed 1023 patients from the Düsseldorf MDS-
registry with regard to the absolute lymphocyte count (ALC) at diagnosis. An ALC below the median of the population
(1.2 × 109/l) was associated with lower counts of neutrophils (median 1.35 vs. 1.92 × 109/l, p < 0.001) and platelets
(median 100 vs. 138 × 109/l, p < 0.001) and with a signiﬁcant lower overall survival in univariate analysis (whole cohort:
median 36 vs. 46 months, p= 0.016; 721 patients without hematopoietic stem cell transplantation or induction
chemotherapy: median 36 vs. 56 months, p= 0.001). For low-risk MDS according to IPSS-R, an ALC < 1.2 × 109/l was of
additional prognostic value in a multivariate Cox regression model together with age (< or ≥65 years) and LDH (< or
≥normal value of 240 U/l; HR 1.46, 95% CI: 1.03–2.08, p= 0.033). These data support the hypothesis of subtle but
clinical relevant changes of the adaptive immune system in MDS. Further studies are necessary to identify the ALC cut-
off best suitable for prognostication and the mechanisms responsible for the impairment of lymphoid homeostasis
in MDS.
Introduction
The myelodysplastic syndromes (MDS) comprise a
heterogeneous group of hematological stem cell disorders
arising primarily in the elderly population. Genetic and
epigenetic changes in hematopoietic stem cells and
alterations in the hematopoietic niche are the main fac-
tors that render hematopoiesis ineffective and increase the
risk of leukemic transformation due to increased genetic
instability.
An accurate risk stratiﬁcation regarding the latter
event is essential for newly diagnosed MDS patients.
The most frequently used score for risk stratiﬁcation,
the international prognostic scoring system (IPSS)1 and
its revised version2 take the degree of cytopenias, the
bone marrow blast count and presence and type of
cytogenetic changes determined by conventional meta-
phase cytogenetics into account. Higher-risk MDS
patients are candidates for allogeneic hematopoietic
stem cell transplantation (HSCT) because of the risk of
leukemic transformation and a very short overall sur-
vival (OS) even without transformation. For lower-risk
MDS patients best supportive care and improvement of
cytopenias are the cornerstones of therapy. Additional
risk factors such as elevated lactate-dehydrogenase
(LDH), bone marrow ﬁbrosis, and recently more and
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more recognized the mutational proﬁle as determined
by next generation sequencing (NGS) are important
additional factors that can be considered for clinical
decision making, especially in intermediate risk patients
according to the IPSS-R3.
A low-lymphocyte count is a prognostic factor in solid
tumors and lymphoid malignancies4. The prevalence and
prognostic impact of lymphopenia in MDS patients has
been studied less systematically. We, therefore, conducted
this study to provide additional evidence with a focus on
MDS subtypes according to the WHO 2016 classiﬁcation,
the IPSS-R and the presence of comorbidities.
Material and methods
We screened the Düsseldorf MDS-registry for patients
with information about the absolute lymphocyte count
(ALC) at diagnosis and the IPSS-R category. The
Düsseldorf MDS-registry covers virtually all newly diag-
nosed MDS-cases in the Greater Düsseldorf Area since
1982. Structure of the registry and the diagnostic criteria
for inclusion of cases have been described earlier in
detail5. The local ethics committee (University Hospital,
Heinrich Heine University, Düsseldorf) approved the
study, which followed the 2000 revision of the Declaration
of Helsinki. All patients gave their written informed
consent before being included into the Düsseldorf MDS
registry.
Patients with an ALC > 5.0 × 109/l were excluded from
the dataset, since they could suffer from a concomitant
lymphoproliferative disorder, as were cases with a white
blood cell count > 13.0 × 109/l, since they could represent
myelodys plastic/myeloproliferative neoplasms. For stra-
tiﬁcation of patients into lymphopenic and non-
lymphopenic, a cut-off of <1.0 × 109/l lymphocytes was
used, according to the normal range of our institutional
laboratory (1.0–4.4 × 109/l). For survival analyses, an ALC
of 1.2 × 109/l was used as an additional discriminator,
since this value was of prognostic relevance in earlier
studies6–8 and represented the median of our cohort.
Data for the MDS comorbidity index (MDS-CI) were
retrieved from the dataset of a study published
previously9.
Categorical variables were analyzed by frequency tables
and compared by the χ2-test, continuous variables were
described by median (range) and compared between dif-
ferent groups by the Mann–Whitney (comparison of two
groups) or the Kruskal–Wallis test (comparison of ≥3
groups), since data did not follow a normal distribution.
Overall and leukemia-free survival were calculated in
months from the date of diagnosis to the respective event
date. Time-to-event-curves were calculated by the
Kaplan–Meier method and the log-rank test was used for
univariate comparison. Cox proportional hazard regres-
sion model was applied for multivariate analysis. All
statistical tests were two-sided and a p value < 0.05 was
considered statistically signiﬁcant. All analyses were per-
formed with IBM SPSS Statistics, Version 25.
Results
Study population
A total of 1023 patients (male n= 598 [58%]; female n
= 425 [42%] with a median age of 66 years (range: 15–91)
were identiﬁed. The median follow-up was 28 months
(range: 0–500). Totally, 645 patients (63%) died during the
follow-up, a leukemic transformation occurred in 254
patients (25%). In all, 117 cases (11%) were therapy-
related following cytotoxic treatment or radiation therapy
for another malignancy or a benign disorder, seven cases
(0.6%) were secondary MDS evolving from another
hematological neoplasm.
Totally, 133 patients (13%) underwent HSCT and 81
(8%) were treated with at least one course of an intensive
induction chemotherapy. The remaining patients
received other disease modifying treatments like
immunomodulatory drugs (Lenalidomide or Thalido-
mide, n= 62) or hypomethylating agents (Azacytidine,
n= 76, Decitabine n= 12), were treated with low-
intensity treatments like erythropoiesis stimulating
agents or immunosuppression (cyclosporine ± anti-thy-
mocyte globulin) or received best supportive care,
including transfusion and iron chelation.
Distribution of MDS subtypes according to the WHO
2016 classiﬁcation, cytogenetic risk groups according to
the IPSS-R and the IPSS-Risk categories, as well as per-
ipheral blood values, blast counts in bone marrow and
peripheral blood and additional parameters (LDH, pre-
sence or absence of bone marrow ﬁbrosis, transfusion
dependency) at the time point of diagnosis are listed in
detail in Table 1.
ALC in the study population, inﬂuence of gender, age, and
comorbidities
The median ALC of the whole population was 1.22 ×
109/l (range: 0.002–4.93). There was no statistically sig-
niﬁcant difference in ALC between patients aged 65 years
or older as compared to 64 years or younger (median
1.18 × 109/l vs. 1.24 × 109/l, p= 0.155) or between patients
within the ﬁrst (15–58 years) and fourth (74–91 years)
quartile of age (median ALC 1.22 × 109/l vs. 1.10 × 109/l,
p= 0.076). Male patients had signiﬁcantly lower ALC
than female patients, albeit with a small difference in
terms of absolute numbers (median 1.17 × 109/l vs. 1.27 ×
109/l, p= 0.027).
The MDS-CI was available in 350 patients, with 200
patients (57%) in the low-risk (score 0), 118 patients (34%)
in the intermediate- (score 1–2) and 32 patients (9%) in
the high-risk category (score > 2). No differences of the
ALC were detected between the different MDS-CI
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categories (median ALC 1.26 × 109/l, 1.19 × 109/l and
1.16 × 109/l, respectively, p= 0.258).
Lymphocyte counts in different MDS subgroups
Despite considerable inter-individual variations of the
ALC, signiﬁcant differences were detected between spe-
ciﬁc MDS subgroups, with a moderate extent in terms of
absolute numbers (see Table 2).
With regard to the WHO2016 classiﬁcation, the ALC
was signiﬁcantly higher in MDS with ring sideroblasts and
single or multilineage dysplasia (MDS-RS-SLD, MDS-RS-
MLD) as compared to MDS with single or multilineage
dysplasia without ring sideroblasts (MDS-SLD, MDS-
MLD; median 1.43 × 109/l vs. 1.09 × 109/l, p < 0.001),
without a signiﬁcant difference between MDS-RS-SLD
and MDS-RS-MLD. Cases with primary MDS showed
higher ALCs than therapy-related MDS (median 1.24 ×
109/l vs. 1.06 × 109/l, p= 0.006). For MDS with isolated
del(5q) as compared to the other subtypes, the difference
was not signiﬁcant (median ALC 1.34 × 109/l vs. 1.19 ×
Table 1 Characteristics of the study population and comparison of several disease characteristics after stratiﬁcation
according to an absolute lymphocyte count < or ≥1.2 × 109/l
Whole population (n= 1023) ALC < 1.2 × 109/l (n= 502) ALC ≥ 1.2 × 109/l (n= 521) p Value
WHO 2016, n (%)
MDS-SLD 75 (7.3) 44 (8.8) 31 (6.0)
MDS-MLD 311 (30.4) 172 (34.3) 139 (26.7)
MDS-RS-SLD 47 (4.6) 16 (3.2) 31 (6.0)
MDS-RS-MLD 93 (9.1) 37 (7.4) 56 (10.7)
MDS(del5q) 115 (11.2) 42 (8.4) 73 (14.0)
MDS-EB-1 167 (16.3) 70 (13.9) 97 (18.6)
MDS-EB-2 203 (19.8) 114 (22.7) 89 (17.1)
MDS-U 12 (1.2) 7 (1.4) 5 (1.0)
IPSS-R, n (%)
Very low 58 (5.7) 24 (4.8) 34 (6.5)
Low 325 (31.8) 148 (29.5) 177 (34)
Intermediate 263 (25.7) 126 (25.1) 137 (26.3)
High 188 (18.4) 92 (18.3) 96 (18.4)
Very high 189 (18.5) 112 (22.3) 77 (14.8)
IPSS-R cytogenetic risk group, n (%)
Very good 36 (3,5) 19 (3.8) 17 (3.3)
Good 624 (61) 287 (57.2) 337 (64.7)
Intermediate 171 (16.7) 92 (18.3) 79 (15.2)
Poor 74 (7.2) 43 (8.6) 31 (6)
Very poor 118 (11.5) 61 (12.2) 57 (10.9)
Age median [years] (range) 66 (15–91) 67 (17–91) 65 (15–86) 0.076
Gender, n (%)
Male 598 (58.5) 310 (61.8) 288 (55.3) 0.036
Leukemic transformation, n (%) 254 (24.8) 119 (23.7) 135 (25.9)
Deaths, n (%) 645 (63) 319 (63,5) 326 (62.6)
Lost to follow-up, n (%) 35 (3.4) 22 (4.4) 13 (2.5)
Hemoglobin, median [g/l] (range) 95 (3–16.9) 93 (3.7–16.9) 97 (3–16.6) 0.04
Neutrophil count, median [×109/l] (range) 1.62 (0–10.59) 1.35 (0.26–10.59) 1.92 (0–10.24) <0.001
Platelet count, median [×109/l] (range) 116 (2–1540) 100 (3–987) 138 (2–1540) <0.001
LDH
Data available, n (%) 869 (84.9) 438 (87.3) 431 (82.7)
LDH, median [U/l] (range) 200 (49–1848) 207 (76–900) 197 (49–1848) 0.049
LDH > ULN [240 U/l], n (%) 274 (31.5) 152 (34.7) 122 (28.3) 0.056
Blasts bone marrow, median [%] (range) 3 (0–19) 3 (0–19) 3 (0–19) 0.577
Blasts peripheral blood, median [%] (range) 0 (0–19) 0 (0–19) 0 (0–19) 0.235
Bone marrow ﬁbrosis data available, n (%) 558 (54.5) 262 (52.2) 296 (56.8)
With bone marrow ﬁbrosis, n (%) 79 (14.2) 31 (11.8) 48 (16.2) 0.146
Transfusion-dependency
Data available, n (%) 425 (41.5) 205 (40.8) 220 (42.2)
Transfusion dependent, n (%) 223 (52.5) 119 (58) 104 (47) 0.032
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109/l, p= 0.054). MDS with excess blasts (MDS-EB-1 and
MDS-EB-2) did not differ from those without excess
blasts.
The ALC was lower in patients with higher-risk MDS
(IPSS-R intermediate, high and very high) compared to
lower-risk MDS (IPSS-R very low and low; median 1.17 ×
109/l vs. 1.28 × 109/l, p= 0.009).
The transfusion status at diagnosis was available for 425
patients. Transfusion-dependency was associated with a
signiﬁcantly lower ALC (median 1.15 × 109/l vs. 1.26 ×
109/l, p= 0.015). Presence or absence of bone marrow
ﬁbrosis did not affect the ALC.
Prevalence of lymphopenia, association with degree of
cytopenias and impact on survival
In all, 38% of patients (n= 387) were lymphopenic,
deﬁned by an ALC < 1.0 × 109/l. Lymphopenic patients
had signiﬁcantly lower counts of platelets (mean 94 × 109/
l vs. 129 × 109/l, p < 0.001) and neutrophils (mean 1.33 ×
109/l vs. 1.81 × 109/l, p < 0.001). The difference for the
Table 2 Distribution of the absolute lymphocyte count in different MDS subtypes
n Median absolute lymphocyte count [×109/l] SD Range p Value
Whole population 1023 1.22 0.76 0.02–4.93
MDS subgroups according to WHO 2016 <0.001
MDS-SLD 75 1.08 0.65 0.07–4.08
MDS-MLD 311 1.11 0.78 0.09–4.93
MDS-RS-SLD 47 1.49 0.74 0.44–3.55
MDS-RS-MLD 93 1.38 0.80 0.02–3.98
MDSdel(5q) 115 1.34 0.62 0.12–3.46
MDS-EB-1 167 1.32 0.70 0.08–3.60
MDS-EB-2 203 1.14 0.83 0.05–4.93
MDS-U 12 1.08 0.94 0.31–3.43
MDS subgroups according to IPSS-R 0.034
IPSS-R very low 58 1.34 0.72 0.22–3.98
IPSS-R low 325 1.27 0.71 0.10–4.09
IPSS-R intermediate 263 1.22 0.77 0.02–4.93
IPSS-R high 188 1.24 0.76 0.08–4.93
IPSS-R very high 189 1.05 0.84 0.05–4.37
MDS with excess blasts 370 1.20 0.78 0.05–4.93
MDS without excess blasts 653 1.22 0.75 0.02–4.93 0.617
MDS del(5q) 115 1.34 0.62 0.12–3.46
MDS non-del(5q) 908 1.19 0.77 0.02–4.93 0.054
MDS-SLD/MLD 385 1.09 0.75 0.07–4.93
MDS-RS-SLD/MLD 140 1.43 0.78 0.02–3.98 <0.001
Lower risk MDS (IPSS-R very low/low) 640 1.17 0.79 0.02–4.93
Higher risk MDS (IPSS-R intermediate/high/very high) 383 1.28 0.71 0.10–4.09 0.009
Therapy-related MDS 117 1.06 0.76 0.02–4.93
Primary MDS 899 1.24 0.76 0.05–4.93 0.006
Transfusion dependent 223 1.15 0.78 0.02–4.37
Transfusion independent 202 1.26 0.71 0.09–3.63 0.015
With bone marrow ﬁbrosis 79 1.31 0.85 0.18–4.37
Without bone marrow ﬁbrosis 479 1.22 0.78 0.02–4.93 0.533
Silzle et al. Blood Cancer Journal            (2019) 9:63 Page 4 of 9
Blood Cancer Journal
degree of anemia was less pronounced (mean hemoglobin
concentration 97 g/l vs. 93 g/l, p= 0.014). Similar differ-
ences were noted with a cut-off of 1.2 × 109/l as dis-
criminator (see Table 1).
As shown in Fig. 1a, an ALC below 1.2 × 109/l was
associated with an inferior OS for the whole population in
univariate analysis (median OS 36 vs. 46 months, p=
0.016; HR for death 1.21, 95% CI: 1.03–1.41, p= 0.017).
An ALC below the normal range (<1.0 × 109/l) as dis-
criminator failed to reach statistical signiﬁcance (median
OS 38 vs. 43 months, p= 0.19; HR for death 0.9, 95% CI:
0.77–1.06, p= 0.194). Hence, an ALC < or ≥1.2 × 109/l
was used as cut-off for further survival analysis.
For patients suffering from secondary MDS or having
received HSCT or induction chemotherapy OS was not
inﬂuenced by lymphopenia (median OS 26 vs. 21 months,
p= 0.89 and 46 vs. 31 months, p= 0.14, respectively).
Due to these ﬁndings, further survival analyses were
restricted to patients suffering from primary MDS without
HSCT or induction chemotherapy (n= 721). The inﬂu-
ence on survival of an ALC < 1.2 × 109/l in this group was
highly signiﬁcant (mean OS 36 vs. 56 months, p= 0.001;
Fig. 1b). It remained an independent prognostic factor in a
multivariate cox regression model together with the
cytogenetic risk groups according to the IPSS-R. However,
after additional inclusion of bone marrow blast count (<
or ≥5%) and level of cytopenias (hemoglobin < or ≥10 g/dl,
absolute neutrophil count < or ≥1.8 × 109/l and platelets <
or ≥100 × 109/l) into the model, an ALC < 1.2 × 109/l lost
its additional prognostic value (p= 0.086, details are
shown in Table 3).
With regard to the different MDS subtypes according to
the WHO2016 classiﬁcation, an ALC < 1.2 × 109/l was
associated with an inferior OS only in MDS-RS-SLD, but
ALC < 1.2 x 109/l (median OS   62 months, n=14)
ALC ≥ 1.2 x 109/l (median OS 155 months, n=28)
ALC < 1.2 x 109/l, censored
ALC ≥ 1.2 x 109/l, censored p<0.001
9/l (median OS   56 months, n=121)
≥ 1.2 x 109/l (median OS 106 months, n=144)
9/l, censored
≥ 1.2 x 109/l, censored p=0.002
ALC < 1.2 x 109/l (median OS 36 months, n=502)
ALC ≥ 1.2 x 109/l (median OS 46 months, n=521)
ALC < 1.2 x 109/l, censored




ALC < 1.2 x 109/l (median OS 36 months, n=344)
ALC ≥ 1.2 x 109/l (median OS 56 months, n=377)
ALC < 1.2 x 109/l, censored
ALC ≥ 1.2 x 109/l, censored p=0.001
B
ALC < 1.2 x 10
ALC 
ALC < 1.2 x 10
ALC 
Fig. 1 a Survival of an unselected MDS cohort (n= 1023) stratiﬁed by an ALC < or ≥1.2×109/l. b Survival of patients with primary MDS, without
induction chemotherapy or stem cell transplantation stratiﬁed by an ALC < or ≥1.2 × 109/l. c Survival of patients with MDS-RS-SLD (n= 42) without
induction chemotherapy or stem cell transplantation stratiﬁed by an ALC < or ≥1.2 × 109/l. d Survival of 265 patients with primary MDS and IPSS-R
low-risk MDS, without induction chemotherapy or stem cell transplantation, stratiﬁed by an ALC < or ≥1.2 × 109/l
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with a high signiﬁcance despite the low patient number (n
= 42; median OS 62 vs. 155 months, p= 0.001; see Fig.
1c). In all other MDS subtypes, no signiﬁcant survival
difference was noted (see Table 4).
After stratiﬁcation according to IPSS-R, the additional
prognostic value of an ALC < 1.2 × 109/l was restricted to
the IPSS-R low-risk group (median OS 56 vs. 106 months,
p= 0.002; see Fig. 1d). It kept its independent prognostic
value for this patient subset after inclusion into a multi-
variable Cox regression model together with age < or ≥65
years and LDH < or ≥normal value (see Table 5).
An ALC < 1.2 × 109/l was not associated with a shorter
leukemia-free survival (mean 22.4 vs. 32.8 months, p=
0.859).
Discussion
Analyzing a large cohort of 1023 uniformly character-
ized patients, we found evidence for a signiﬁcant
impairment of lymphopoiesis in MDS. Totally, 38% of
patients were lymphopenic (ALC < 1.0 × 109/l) and the
median lymphocyte count of 1.22 × 109/l observed in our
cohort was conssiderably lower than the median ALC of
about 2.0 × 109/l, published for a large cohort of healthy,
nonhispanic caucasian US Americans in the correspond-
ing age groups10. In addition, an ALC < 1.2 × 109/l was
associated with a worse OS in univariate analysis.
These results are consistent with previously published
data on lymphopenia in MDS and its impact on survival.
A prognostic role for an ALC < 1.2 × 109/l in MDS with
del(5q), including patients with an increased blast count
and additional cytogenetic abnormalities, was ﬁrst
reported by Holtan et al.6. Subsequently, a lymphopenia
deﬁned by this cut-off was considered to be an indepen-
dent prognostic factor in addition to IPSS and WPSS in
MDS without del(5q) as well7. Within an unselected
cohort of primary MDS, an ALC < 1.2 × 109/l was asso-
ciated with an inferior OS in univariate analysis but failed
to reach statistical signiﬁcance, when including the more
reﬁned cytogenetic risk categories according to IPSS-R
into a multivariate Cox regression model8.
In addition to the conﬁrmation of these previous
observations in an independent cohort, our ﬁndings add
some new aspects to the role of lymphopenia in MDS.
First, the additional prognostic value of a low-lymphocyte
count seems to be restricted to low-risk patients, if the
IPSS-R is used for risk stratiﬁcation. However, for this
subgroup it can be considered as a relative strong addi-
tional prognostic marker, since it retained its indepen-
dent prognostic value in a multivariate Cox regression
model together with age and an elevated LDH, two
additional risk factors well-known to affect prognosis in
MDS2,11.
Table 3 Factors affecting prognosis in MDS patients without hematopoietic stem cell transplantation or induction
chemotherapy (n= 721) in univariate analysis and two multivariate models (multivariate I: absolute lymphocyte count <
1.2 × 109/l together with the cytogenetic risk groups according to IPSS-R; multivariate II: absolute lymphocyte count <
1.2 × 109/l together with the cytogenetic risk groups according to IPSS-R, bone marrow blast count and the degree of
cytopenias)
Univariate Multivariate I Multivariate II
p Hazard ratio 95% conﬁdence
interval
p Hazard ratio 95%
conﬁdence interval p Hazard ratio 95% conﬁdence
interval
Age ≥ 65 <0.001 2.32 1.87 2.86
Male gender 0.005 1.15 1.04 1.26
Hb < 10 g/dl <0.001 1.47 1.21 1.78 <0.001 1.56 1.29 1.89
Neutrophil count < 1.8 × 109/l 0.001 1.39 1.15 1.67 0.959 1.0 0.82 1.23
Platelet count < 100 × 109/l <0.001 1.88 1.56 2.27 <0.001 1.56 1.28 1.89
Bone marrow blasts > 5% <0.001 2.60 2.13 3.18 <0.001 2.25 1.82 2.79
IPSS-R cytogenetic risk category <0.001 1.55 1.41 1.69 <0.001 1.52 1.39 1.67 <0.001 1.38 1.26 1.51
IPSS-R category <0.001 1.68 1.55 1.82
Transfusion dependency 0.001 1.73 1.27 2.36
LDH > ULN (240 U/l) <0.001 1.91 1.53 2.38
Absolute lymphocyte count < 1.2 × 109/l 0.001 1.35 1.13 1.63 0.022 1.24 1.03 1.49 0.086 0.85 0.70 1.02
Silzle et al. Blood Cancer Journal            (2019) 9:63 Page 6 of 9
Blood Cancer Journal
The lack of an additional prognostic value for the IPSS-
R very low-risk category in our cohort may be due to the
very low patient number in this cohort (n= 51). Biology
and clinical course of high-risk and very high-risk MDS
are primarily characterized by genomic instability and
AML evolution. In this setting, an additional impairment
Table 4 Impact of the absolute lymphocyte count on survival in 721 MDS patients without hematopoietic stem cell
transplantation or induction chemotherapy according to MDS subtypes
Median OS [months] Median OS [months]
n ALC < 1.2 × 109/l 95% CI ALC ≥ 1.2 × 109/l 95% CI p log rank
Whole cohort 721 36 29–43 56 48–64 0.001
Subgroups according to WHO2016
MDS-SLD 57 not reached n.a 141 26–256 0.271
MDS-MLD 227 40 26–54 44 30–58 0.433
MDS-RS-SLD 42 62 2–122 155 29–281 <0.001
MDS-RS-MLD 66 47 19–75 70 44–96 0.310
MDS del(5q) 102 62 48–76 77 47–107 0.174
MDS-EB-1 108 19 6–32 25 19–31 0.291
MDS-EB-2 109 11 6–16 22 14–30 0.268
MDS-U 10 95 n.a. 63 n.a. 0.757
Risk categories according to IPSS-R
IPSS-R very low 51 101 42–160 104 71–137 0.731
IPSS-R low 265 56 46–66 106 70–142 0.002
IPSS-R intermediate 187 50 33–67 41 31–51 0.639
IPSS-R high 121 29 19–39 24 19–29 0.538
IPSS-R very high 97 8 6–10 13 9–17 0.127
Table 5 Additional prognostic value of different factors for patients within the IPSS-R low-risk group without
hematopoietic stem cell transplantation or induction chemotherapy (n= 265)
Unvariate Multivariate
p Value Hazard ratio 95% CI p Value Hazard ratio 95% CI
Age > 65 <0.001 3.31 2.25 4.88 <0.001 3.21 2.15 4.80
LDH > ULN (240 U/l) <0.001 2.31 1.51 3.53 <0.001 2.58 1.67 3.98
Absolute lymphocyte count <1.2 × 109/l 0.002 1.68 1.21 2.34 0.033 1.46 1.03 2.08
Male gender 0.054 1.39 0.99 1.93
Transfusion dependency 0.075 1.61 0.95 2.71
Bone marrow ﬁbrosis 0.691 0.87 0.45 1.69
Hb < 10 g/dl 0.287 1.20 0.86 1.66
Neutrophil count < 1.8 × 109/l 0.148 0.79 0.57 1.09
Platelet count < 100 × 109/l 0.174 0.73 0.47 1.15
Bone marrow blasts > 5% 0.916 1.04 0.49 2.23
IPSS-R cytogenetic risk category 0.213 1.44 0.81 2.57
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of the adaptive immune system does not seem to have
additional prognostic value.
Alterations of both the innate and the adaptive immune
system have long been recognized as a feature in
MDS12,13. The T-cell compartment has been most
extensively studied, with a focus on its involvement in the
pathophysiology of MDS. To date, it is unknown, whether
lymphopenic MDS patients differ from MDS patients with
a normal lymphocyte count with regard to the distribu-
tion or functional capacity of different lymphocyte sub-
sets. Whether lymphopenia in MDS is a direct
consequence of underlying hematopoietic stem cell defect
(s) or arises from immune-modulating stimuli related to
the disease or to other host conditions remains to be
elucidated as well.
Here, some of our observations point towards a direct
relationship between MDS pathophysiology and low
lymphocyte counts. In our cohort, neither age nor
comorbidities were associated with a lower ALC and
signiﬁcant differences with regard to the ALC were noted
between different MDS subtypes. Notably, ALCs were
lower in subtypes with a worse prognosis, like higher-risk
MDS according to the IPSS-R, cases of therapy related
MDS and in patients being transfusion dependent at
diagnosis. In addition, lymphopenia was associated with
lower peripheral blood counts as markers of disease
severity, a ﬁnding that has been described previously8.
Some of the key features of T-cell alterations seen in
aging individuals14 have also been described as features of
T-cell lymphopoiesis in MDS, as for example a skewed T-
cell receptor repertoire15 and a contracted pool of CD8+
T cells16. Hence, the overlapping features of the physiol-
ogy of aging hematopoiesis and the pathophysiology of
MDS, which have come into focus recently17, may provide
some explanations for the lymphopenia occurring in
MDS-patients.
Many changes of the adoptive immune system in the
elderly, often referred to as immunosenescence, can be
directly traced back to changes in the stem cell com-
partment, which typically shows a myeloid-skewing with
a diminished capacity for lymphoid differentiation18.
Subclinical inﬂammatory changes in the bone marrow
microenvironment are a further hallmark of the aging
hematopoietic stem cell niche19. Recently, microin-
ﬂammation in the bone marrow mediated by the NLRP3
inﬂammasome has been identiﬁed as one driver of the
MDS phenotype20 and activation of the NLRP3-
inﬂammasome within the bone marrow is known to
inhibit B-cell lymphopoiesis at least in vitro21. Addi-
tional alterations in the bone marrow niche linking
impairment of lymphopoiesis and inﬂammatory changes
likely exist and may not only cause ineffective hemato-
poiesis, but also compromise homeostasis of both B and
T cells.
Furthermore, lymphocytes can be part of the MDS-
clone. For MDS with del(20q)22, Monosomy 7 (ref. 23),
trisomy 8 (ref. 24) and del(5q)23, the respective cytogenetic
anomalies have been described in B- and/or T-cell lym-
phocytes, leading to the hypothesis that the MDS clones
arise in a common myeloid and lymphoid progenitor at
least in some cases. This was demonstrated in a study
applying NGS to bone marrow cell populations sorted
according to their differentiation stage in MDS-RS-SLD24.
The initiating SF3B1 mutation was found in a lympho-
myeloid progenitor and is consistently detectable at the
pro-B-cell progenitor stage. Since the mutation was rarely
observed in mature B cells, it can be concluded that
SF3B1-mutations are likely to impair B-cell development.
Concerning T-cell involvement in myeloid neoplasms,
mutations in the epigenetic regulator DNMT3A are
detectable in AML patients in both leukemic blasts and in
T cells at diagnosis25, and may persist in ﬁrst complete
remission in both compartments26. Since DNMT3A has
recently been shown to be involved in T-cell develop-
ment27, DNMT3A mutations may affect T-cell biology
and due to the many pathways shared between MDS and
AML, MDS could be derived from lympho-myeloid clonal
hematopoiesis at least in some subtypes. However, the
clonal involvement of T cells in MDS remains to be stu-
died systematically.
Both Lenalidomide28,29, and hypomethylating agents30
alter lymphocyte biology during treatment. Hence, these
treatments could possibly be able to reverse the negative
prognostic impact of a lymphopenia at diagnosis. Only a
limited number of patients in our cohort were treated
with these compounds, so we are not able to address the
question whether a low ALC remains a signiﬁcant prog-
nostic factor in patients treated with Lenalidomide and
hypomethylating agents. Further studies addressing this
question are needed. Since the ALC is readily available in
clinical routine this question can be addressed in clinical
trials or register studies. Furthermore, the additional
prognostic value of the ALC should be investigated after
reﬁnement of the IPSS-R by the inclusion of adverse
molecular features revealed by NGS31.
Taken together, our data support the hypothesis of
subtle but clinically relevant changes of the adaptive
immune system in MDS. Further studies are necessary to
deﬁne the ALC cut-off most suitable for prognostication
and to identify the mechanisms underlying the impair-
ment of lymphoid homeostasis in MDS.
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